248 related articles for article (PubMed ID: 31369575)
1. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis.
Castagné B; Viprey M; Martin J; Schott AM; Cucherat M; Soubrier M
PLoS One; 2019; 14(8):e0220178. PubMed ID: 31369575
[TBL] [Abstract][Full Text] [Related]
2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
5. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
Matsuno H; Katayama K
Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
10. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
13. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
14. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Kawabe A; Nakano K; Kubo S; Asakawa T; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):136. PubMed ID: 32513309
[TBL] [Abstract][Full Text] [Related]
15. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
16. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
17. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
[TBL] [Abstract][Full Text] [Related]
18. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
19. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.
Maneiro RJ; Salgado E; Carmona L; Gomez-Reino JJ
Semin Arthritis Rheum; 2013 Aug; 43(1):9-17. PubMed ID: 23290690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]